SSY GROUP(02005): Obtained the drug production registration approval for 0.2g indobufen tablets.

12:21 14/11/2025

Shi Si Pharmaceutical Group (02005) announced that the group has obtained approval from the Chinese National Medical Products Administration for indomethacin tablets (...

SSY GROUP (02005) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for indobufen tablets (0.2g), which belong to the third category of chemical drugs and are considered to have passed consistency evaluation. Indobufen tablets are mainly used to treat ischemic cardiovascular diseases and ischemic cerebrovascular diseases caused by arteriosclerosis, as well as to prevent thrombosis during hemodialysis.

HK Stock Market Move | China International Marine Containers (02039) surged over 7% in the afternoon, with energy storage containers attracting market attention. The company has strong cost competitiveness.

HK Stock Market Move | XPENG-W (09868) fell more than 5%, still up over 1.1 times year-to-date. The third-quarter report will be released next week.

Highlighting the growth potential and stable high dividend of TSUGAMI CHINA (01651), the interim report confirms the growth rationale.

HK Stock Market Move | XPENG-W (09868) fell more than 5%, still up over 1.1 times year-to-date. The third-quarter report will be released next week.

Highlighting the growth potential and stable high dividend of TSUGAMI CHINA (01651), the interim report confirms the growth rationale.